Clinical

Pharmacy Pearls: How to Identify a Ruptured Brain Aneurysm and Subarachnoid Hemorrhage

By: Maha Sohail, PharmD Candidate c/o 2024 In the United States, about 6.5 million, or 1 in 50 people, have…

3 years ago

It’s in Our Blood: An Exploration of Gene Therapies for Hemophilia A and B

By: Holly Nguyen, PharmD Candidate ℅ 2024 Hemophilia is a severe hereditary hemorrhagic disorder derived from gene mutations that make…

3 years ago

Efficacy of Cabozantinib, Nivolumab, and Ipilimumab Combination Therapy in Advanced Clear-Cell Renal-Cell Carcinoma

By: Shakhzoda Rakhimova, PharmD Candidate ℅ 2024 Introduction Renal-cell carcinoma (RCC) is a type of kidney cancer in which malignant…

3 years ago

The Current Landscape of Treatment Options for Alzheimer’s Disease

By: Anureet Kaur, PharmD Candidate c/o 2024  Alzheimer’s disease (AD) is an epidemic. Currently, the neurodegenerative disorder holds the title…

3 years ago

The Use of Nitric Oxide Nasal Spray in Mild COVID-19 Infections

By: Isabelle Lim, PharmD Candidate c/o 2024 and Hadeel Aldasooky, PharmD Candidate c/o 2024 As the threat of coronavirus disease…

3 years ago

Evaluation of Haloperidol for Treatment of ICU Delirium

By: Nancy Yousry, PharmD Candidate c/o 2024 Delirium is characterized as impaired cognition with a wide range of manifestations that…

3 years ago

Evaluation of Ivermectin for Treatment of COVID-19

By: Isabelle Lim, PharmD Candidate c/o 2024 and Justin Budz, PharmD Candidate c/o 2023 Coronavirus disease 2019 (COVID-19) is an…

3 years ago

A Beacon of Hope for Multi-Drug Resistant HIV Patients: Sunlenca®

By: Debika Kundu, PharmD Candidate c/o 2024 and Jeilyn Nunez, PharmD Candidate c/o 2025 Human immunodeficiency virus (HIV) is a…

3 years ago

Assessing the Efficacy of Cholecalciferol Versus Ergocalciferol for Vitamin D Repletion in Chronic Kidney Disease

By: Nancy Yousry, PharmD Candidate c/o 2024               Vitamin D is a multifaceted nutrient needed to maintain homeostasis and proper…

3 years ago

Evaluating Efficacy of Bortezomib and Carfilzomib in Treatment of Refractory Multiple Myeloma

By: Brian Chung, PharmD Candidate c/o 2024, Peter Chung, PharmD Candidate c/o 2024, and Kevin Kim, PharmD Candidate c/o 2024…

3 years ago